{"id":996972,"date":"2026-08-20T08:55:01","date_gmt":"2026-08-20T12:55:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/"},"modified":"2026-08-20T08:55:01","modified_gmt":"2026-08-20T12:55:01","slug":"artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/","title":{"rendered":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13"},"content":{"rendered":"
\n

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc.<\/a>\u00a0(Nasdaq:\u00a0ARTL) <\/strong>(\u201cArtelo\u201d or the \u201cCompany\u201d),<\/strong>\u00a0a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company\u2019s patent application covering the intended commercial formulation of ART27.13, Artelo\u2019s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.<\/p>\n

The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. This brings Artelo\u2019s intellectual property estate for ART27.13 to issued or allowance status in three major pharmaceutical markets, the United States, Japan, and Europe, and further strengthens the program\u2019s global IP position while supporting its long-term commercial potential.<\/p>\n

\u201cReceiving this allowance decision in Japan represents another important advancement in our global intellectual property and clinical development strategy for ART27.13,\u201d said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. \u201cThe innovator of our investigational drug, AstraZeneca, previously conducted a Phase 1 safety study with ART27.13 in Japan, with no major safety or tolerability concerns, and had concluded the plasma exposure and adverse event profiles were comparable between Japanese and Caucasian participants.\u201d ART27.13 was fully licensed to Artelo in 2019.<\/p>\n

Currently being evaluated in the Phase 2 portion of CAReS targeting cancer-related anorexia, ART27.13 was well-tolerated in the Phase 1 stage and showed early signs of stabilizing or reversing weight loss in more than 60% of participants. Interim results from the CAReS Phase 2 demonstrated the ability of the drug to reverse cancer-related anorexia in all patients taking the highest dose of 1300 \u00b5g whereas the all the participants on placebo continued to lose weight throughout the study.<\/p>\n

ART27.13 is also being evaluated in the DREAM study, a pilot Phase 2 in people with glaucoma or ocular hypertension. Funded by Glaucoma UK and the HSC R&D Division in the UK, the investigator-led study is evaluating ART27.13’s potential at a 600 \u00b5g orally administered daily dose to reduce intraocular pressure, alongside additional assessments of visual acuity, body weight, mood, safety and tolerability. Initial results are anticipated in the fourth quarter of this year.<\/p>\n

\u201cWith allowances now secured in the United States, Europe and Japan for claims covering our intended commercial formulation, we believe we have established a strong foundation for ART27.13 across three of the world\u2019s major pharmaceutical markets. This growing patent estate further enhances the strategic and commercial value of the program as ART27.13 advances in multiple potential indications,\u201d concluded Mr. Gorgas.<\/p>\n

\n About\u00a0ART27.13<\/strong>
\n
ART27.13 is a dual cannabinoid agonist and novel benzimidazole derivative. Initially developed by AstraZeneca plc, ART27.13 has been in\u00a0over seven clinical studies with nearly 300 participants. It is primarily being developed as a once-daily, orally administered agent selectively targeting peripheral CB1<\/sub>\u00a0and CB2\u00a0<\/sub>receptors, with the potential to reduce muscle degeneration while improving body weight, appetite, and quality of life in cancer patients. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Interim Phase 2 data revealed patients who had lost at least 5% of body weight to be included in CAReS and titrated to the highest ART27.13 dose (1300 \u00b5g) achieved an average +6% weight gain over 12 weeks, while patients on placebo lost an additional ~5%. Currently, there is no FDA approved treatment for cancer anorexia cachexia syndrome. In addition to CAReS, ART27.13 is also being evaluated in a Phase 2 study in people with glaucoma, called the DREAM study. In DREAM, ART27.13 is administered orally at a daily dose of 600 \u00b5g.\u00a0\u00a0<\/p>\n

\n About Artelo Biosciences<\/strong>
\n
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at\u00a0www.artelobio.com<\/a>\u00a0and X: @ArteloBio.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
\n This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company\u2019s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.<\/em>\n <\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc.\u00a0(Nasdaq:\u00a0ARTL) (\u201cArtelo\u201d or the \u201cCompany\u201d),\u00a0a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company\u2019s patent application covering the intended commercial formulation of ART27.13, Artelo\u2019s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. … <\/p>\n

Continue reading “Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-996972","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArtelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc.\u00a0(Nasdaq:\u00a0ARTL) (\u201cArtelo\u201d or the \u201cCompany\u201d),\u00a0a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company\u2019s patent application covering the intended commercial formulation of ART27.13, Artelo\u2019s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. … Continue reading "Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T12:55:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13\",\"datePublished\":\"2026-08-20T12:55:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/\"},\"wordCount\":1015,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/\",\"name\":\"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=\",\"datePublished\":\"2026-08-20T12:55:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/","og_locale":"en_US","og_type":"article","og_title":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk","og_description":"SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc.\u00a0(Nasdaq:\u00a0ARTL) (\u201cArtelo\u201d or the \u201cCompany\u201d),\u00a0a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company\u2019s patent application covering the intended commercial formulation of ART27.13, Artelo\u2019s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. … Continue reading \"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-20T12:55:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13","datePublished":"2026-08-20T12:55:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/"},"wordCount":1015,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/","name":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=","datePublished":"2026-08-20T12:55:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMzE5NiM3Nzg1MDU4IzIxODc1NzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=996972"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996972\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=996972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=996972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=996972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}